HK1206035A1 - Igg stimulated remyelination of peripheral nerves igg - Google Patents

Igg stimulated remyelination of peripheral nerves igg

Info

Publication number
HK1206035A1
HK1206035A1 HK15106445.1A HK15106445A HK1206035A1 HK 1206035 A1 HK1206035 A1 HK 1206035A1 HK 15106445 A HK15106445 A HK 15106445A HK 1206035 A1 HK1206035 A1 HK 1206035A1
Authority
HK
Hong Kong
Prior art keywords
igg
peripheral nerves
remyelination
stimulated
stimulated remyelination
Prior art date
Application number
HK15106445.1A
Other languages
English (en)
Chinese (zh)
Inventor
Patrick Kuery
Nevena Tzekova
Hans-Peter Hartung
Corinna Hermann
Birgit Maria Reipert
Hans-Peter Schwarz
Hartmut Ehrlich
Sebastian Bunk
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of HK1206035A1 publication Critical patent/HK1206035A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
HK15106445.1A 2012-02-29 2015-07-07 Igg stimulated remyelination of peripheral nerves igg HK1206035A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
PCT/US2013/028350 WO2013130826A2 (fr) 2012-02-29 2013-02-28 Remyélinisation stimulée par igg de nerfs périphériques

Publications (1)

Publication Number Publication Date
HK1206035A1 true HK1206035A1 (en) 2015-12-31

Family

ID=47884569

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15106445.1A HK1206035A1 (en) 2012-02-29 2015-07-07 Igg stimulated remyelination of peripheral nerves igg
HK18108139.5A HK1248534A1 (zh) 2012-02-29 2018-06-25 周圍神經的igg刺激髓鞘再生

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18108139.5A HK1248534A1 (zh) 2012-02-29 2018-06-25 周圍神經的igg刺激髓鞘再生

Country Status (21)

Country Link
US (5) US8986670B2 (fr)
EP (2) EP2820042B1 (fr)
JP (3) JP6335800B2 (fr)
KR (3) KR20200126005A (fr)
CN (4) CN109966488A (fr)
AR (2) AR090211A1 (fr)
AU (3) AU2013203088B2 (fr)
BR (1) BR112014021240A2 (fr)
DK (2) DK3590960T3 (fr)
EA (2) EA032000B1 (fr)
ES (2) ES2943585T3 (fr)
FI (1) FI3590960T3 (fr)
HK (2) HK1206035A1 (fr)
IL (3) IL274512B2 (fr)
MX (2) MX369444B (fr)
NZ (1) NZ629867A (fr)
PL (2) PL3590960T3 (fr)
PT (2) PT3590960T (fr)
SG (1) SG11201405302WA (fr)
TW (3) TW201838654A (fr)
WO (1) WO2013130826A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
WO2020146370A1 (fr) * 2019-01-07 2020-07-16 Mallinckrodt Ard Ip Limited Procédés de promotion de la remyélinisation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (fr) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
ATE36457T1 (de) 1983-05-02 1988-09-15 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンg結合活性を有する新規な蛋白質プロテインh、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
AU8649391A (en) * 1990-08-15 1992-03-17 University Of Miami Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
JP3133338B2 (ja) 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
AU753468B2 (en) 1998-06-09 2002-10-17 Csl Behring Ag Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
AU2000261978B2 (en) * 2000-05-10 2006-07-06 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
EP1592387A4 (fr) 2003-01-24 2009-05-06 Elan Pharm Inc Composition permettant de traiter des maladies dues a la demyelinisation et a la paralysie par administration d'agents de remyelinisation
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
PT1718675E (pt) 2004-02-27 2013-05-21 Octapharma Ag Método de proporcionar uma preparação purificada de anticorpos livre de vírus
NZ578816A (en) * 2007-02-02 2012-06-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (fr) 2008-11-06 2015-02-03 Michael Fehlings Utilisation therapeutique d'igg en tant qu'agent neuroprotecteur
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法

Also Published As

Publication number Publication date
HK1248534A1 (zh) 2018-10-19
AR090211A1 (es) 2014-10-29
KR102673154B1 (ko) 2024-06-05
US20130224150A1 (en) 2013-08-29
EP3590960A1 (fr) 2020-01-08
IL274512B1 (en) 2024-03-01
KR20220045087A (ko) 2022-04-12
KR102170615B1 (ko) 2020-10-28
PT2820042T (pt) 2019-10-31
EA032000B1 (ru) 2019-03-29
WO2013130826A3 (fr) 2013-12-05
US8986670B2 (en) 2015-03-24
DK2820042T3 (da) 2019-10-28
EP2820042A2 (fr) 2015-01-07
AU2016201137A1 (en) 2016-03-10
US20200216518A1 (en) 2020-07-09
TW201400502A (zh) 2014-01-01
IL234303B (en) 2020-09-30
KR20140134690A (ko) 2014-11-24
AU2018200026B2 (en) 2019-12-05
JP2020059705A (ja) 2020-04-16
PT3590960T (pt) 2023-04-18
PL3590960T3 (pl) 2023-07-17
US20150232536A1 (en) 2015-08-20
TWI700297B (zh) 2020-08-01
MX369444B (es) 2019-11-08
PL2820042T3 (pl) 2020-03-31
ES2755056T3 (es) 2020-04-21
EA201400966A1 (ru) 2014-12-30
JP2015508824A (ja) 2015-03-23
CN109966488A (zh) 2019-07-05
US20210300997A1 (en) 2021-09-30
JP6335800B2 (ja) 2018-05-30
AU2013203088B2 (en) 2015-12-03
EA201892521A1 (ru) 2019-07-31
CN104302666A (zh) 2015-01-21
IL274512A (en) 2020-06-30
ES2943585T3 (es) 2023-06-14
MX2014010387A (es) 2015-09-25
AU2013203088A1 (en) 2013-09-19
IL277103A (en) 2020-10-29
JP6979990B2 (ja) 2021-12-15
CN107551269A (zh) 2018-01-09
AU2016201137B2 (en) 2017-10-12
FI3590960T3 (fi) 2023-04-25
TW201736398A (zh) 2017-10-16
EP2820042B1 (fr) 2019-07-24
MX2019012496A (es) 2020-01-20
AR117207A2 (es) 2021-07-21
SG11201405302WA (en) 2014-09-26
NZ629867A (en) 2016-09-30
IL274512B2 (en) 2024-07-01
KR20200126005A (ko) 2020-11-05
CN110343171A (zh) 2019-10-18
BR112014021240A2 (pt) 2018-09-18
TWI632158B (zh) 2018-08-11
AU2018200026A1 (en) 2018-01-25
WO2013130826A2 (fr) 2013-09-06
JP6637934B2 (ja) 2020-01-29
DK3590960T3 (da) 2023-04-24
EP3590960B1 (fr) 2023-03-29
US10494418B2 (en) 2019-12-03
JP2018030856A (ja) 2018-03-01
US20180291087A1 (en) 2018-10-11
TW201838654A (zh) 2018-11-01
US9834593B2 (en) 2017-12-05

Similar Documents

Publication Publication Date Title
EP2925327A4 (fr) Activité anticonvulsivante des stéroïdes
GB201220573D0 (en) Methods of diagnosing proliferative disorders
ZA201406082B (en) Use of ccr3-inhibitors
IL234813A0 (en) Methods for increasing the efficacy of cd37-based therapy
IL277103A (en) IgG-stimulated remodeling of peripheral nerve myelin
PT2812013T (pt) Formulação para o tratamento do sii
GB201117707D0 (en) Stimulator
GB201309274D0 (en) Treatment Of Fuel
PL2882880T3 (pl) Obróbka materiałów zawierających mangan
SG11201403246PA (en) Treatment of manganese-containing materials
EP2852411A4 (fr) Anticorps anti-ccl2 pour le traitement de la sclérodermie
EP2908871A4 (fr) Techniques de traitement des abcès
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201212717D0 (en) Treatment of musculoskeletal conditions
GB201221032D0 (en) Method of treatment
GB201207528D0 (en) Places of excellence
TWM433525U (en) Structure of calorifier
GB201221046D0 (en) Method of diagnosis
GB201207894D0 (en) Method of treatment